A Sound Rationale Needed for Phase III HIV-1 Vaccine Trials

Science

Volumn 303, Issue 5656, 2004, Pages 316-

  Burton, Dennis R ^a   Desrosiers, Ronald C ^b   Doms, Robert W ^c   Feinberg, Mark B ^d   Gallo, Robert C ^e   Hahn, Beatrice ^f   Hoxie, James A ^c   Hunter, Eric ^f   Korber, Bette ^g   Landay, Alan ^h   Lederman, Michael M ⁱ   Lieberman, Judy ^b   McCune, Joseph M ^j   Moore, John P ^k   Nathanson, Neal ^c   Picker, Louis ^l   Richman, Douglas ^m   Rinaldo, Charles ⁿ   Stevenson, Mario ^o   Watkins, David I ^p   Wolinsky, Steven M ^q   Zack, Jerome A ^r   more..

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d EMORY UNIVERSITY   (United States)

^e INSTITUTE OF HUMAN VIROLOGY   (United States)

^f UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^g SANTA FE INSTITUTE   (United States)

^h RUSH MEDICAL COLLEGE   (United States)

ⁱ CASE WESTERN RESERVE UNIVERSITY   (United States)

^j GLADSTONE INSTITUTE OF VIROLOGY AND IMMUNOLOGY   (United States)

^k WEILL CORNELL MEDICAL COLLEGE   (United States)

^l OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF PITTSBURGH   (United States)

^o UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^p UNIVERSITY OF WISCONSIN MADISON   (United States)

^q NORTHWESTERN UNIVERSITY   (United States)

^r UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; RECOMBINANT VACCINE;

VACCINE;

CANARYPOX VIRUS; CELLULAR IMMUNITY; CLINICAL TRIAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMORAL IMMUNITY; IMMUNOGENETICS; IMMUNOGENICITY; INFECTION CONTROL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; SHORT SURVEY; VIRUS INHIBITION; ARTICLE; BIOMEDICAL AND BEHAVIORAL RESEARCH; COST; CYTOTOXIC T LYMPHOCYTE; ECONOMICS; HELPER CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOLOGY; THAILAND; UNITED STATES;

CANARYPOX VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

BIOMEDICAL AND BEHAVIORAL RESEARCH;

AIDS VACCINES; CLINICAL TRIALS, PHASE III; COSTS AND COST ANALYSIS; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; T-LYMPHOCYTES, CYTOTOXIC; T-LYMPHOCYTES, HELPER-INDUCER; THAILAND; UNITED STATES; VACCINES, SYNTHETIC;

EID: 1342332108     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1094620     Document Type: Short Survey

References (8)

1. J. Cohen, Science 302, 1309 (2003).
2. J. Cohen, Science 299, 1290 (2003).
3. J. Cohen, Science 295, 1616 (2002).
4. M. L. Clements-Mann et al. J. Infect Dis. 177, 1230 (1998).
5. G. J. Gorse et al., Vaccine 19, 1806 (2001).
6. S. Ratto-Kim et al, J. Acquir. Immune Defic. Syndr. 32, 9 (2003).
7. J. Cohen, Shots in the Dark: The Wayward Search for an AIDS Vaccine (Norton, New York, 2001).
8. R. I. Connor et al., J. Virol. 72, 1552 (1998).